Thymulin is strictly for laboratory research and is commonly employed in the following investigational areas:

Neuroinflammation and Analgesia

Thymulin is a potent tool for studying inflammatory hyperalgesia. In rat models, intracerebroventricular (i.c.v.) administration of Thymulin has been shown to reverse endotoxin-induced hyperalgesia. Researchers use it to investigate the downregulation of spinal pro-inflammatory cytokines (TNF-α, IL-6) and the inhibition of p38 MAPK phosphorylation in microglia.

T-Cell Differentiation and Immunity

As a classical thymic hormone, Thymulin is used to study T-cell maturation. It promotes the expression of T-cell markers and enhances T-cell functions, including suppressor activity and cytotoxicity. Research often focuses on its role in normalizing the T-helper/T-suppressor ratio in immunodeficient models.

Asthma and Airway Remodeling

In respiratory research, Thymulin gene therapy (using DNA nanoparticles) is investigated for its potential to prevent airway remodeling. Studies in ovalbumin-challenged mice demonstrate that Thymulin expression can reduce lung inflammation, collagen deposition, and smooth muscle hypertrophy, improving overall lung mechanics.

Neuroendocrine Regulation

Thymulin is used to map the feedback loops between the thymus and the pituitary gland. It serves as a probe to study how hormones like GH, prolactin, and thyroxine influence thymic endocrine function, and conversely, how Thymulin stimulates the release of pituitary hormones such as LH and ACTH.

Pathway / Mechanistic Context

The primary mechanisms of action for Thymulin in research settings involve zinc-dependent receptor modulation and cytokine regulation.

• Zinc Activation: Thymulin binds free zinc ions to become active, influencing zinc bioavailability and serving as a sensor for physiological zinc status.
• Cytokine Suppression: In the CNS, Thymulin reduces the production of pro-inflammatory mediators (IL-1β, IL-6, TNF-α) by glial cells, thereby acting as a neuroprotective and analgesic agent.
• p38 MAPK Inhibition: Its analgesic effects are mechanistically linked to the inhibition of p38 mitogen-activated protein kinase (MAPK) phosphorylation in spinal microglia, interrupting pain signaling pathways.

Preclinical Research Summary

Published preclinical literature documents investigations of Thymulin across multiple experimental models:

• Inflammatory Pain: Preclinical studies demonstrate that Thymulin pretreatment dose-dependently reduces mechanical and thermal hyperalgesia induced by CFA or endotoxins, confirming its role in modulating nociceptive thresholds.
• Allergic Asthma: Gene therapy delivering Thymulin in murine asthma models resulted in a significant reduction of inflammatory infiltrates and prevention of structural airway changes, suggesting therapeutic potential for chronic lung diseases.
• Sepsis and Inflammation: Thymulin has been shown to reduce the levels of pro-inflammatory cytokines in the brain following systemic endotoxin challenge, highlighting its capacity to mitigate neuroinflammation associated with sepsis-like states.

Form & Analytical Testing

This material is produced via robust solid-phase peptide synthesis and supplied as a lyophilized (freeze-dried) powder.

• Lyophilization: Removes water content under vacuum to maintain peptide integrity and extend shelf-life.
• Identity Verification: Each lot undergoes Mass Spectrometry (MS) to confirm molecular weight and identity.
• Purity Verification: High-Performance Liquid Chromatography (HPLC) is performed to ensure the product meets the ≥99% purity standard required for reproducible research data.

Referenced Citations

References are provided for informational purposes only and are not clinical claims.

• [1.1] Reggiani, P. C., et al. (2009). The Thymus–Neuroendocrine Axis: Physiology, Molecular Biology, and Therapeutic Potential of the Thymic Peptide Thymulin. Annals of the New York Academy of Sciences. https://pmc.ncbi.nlm.nih.gov/articles/PMC2688715/
• [1.2] (2020). Investigating the Gene Coding for Thymulin. University of Innsbruck. https://diglib.uibk.ac.at/download/pdf/3675910.pdf
• [1.3] Reggiani, P. C., et al. (2011). Thymulin-Based Gene Therapy and Pituitary Function in Animal Models of Aging. Neuroimmunomodulation. https://pmc.ncbi.nlm.nih.gov/articles/PMC3221262/
• [2.1] Safieh-Garabedian, B., et al. (2003). Thymulin reverses inflammatory hyperalgesia and modulates the increased concentration of proinflammatory cytokines induced by i.c.v. endotoxin injection. Neuroscience. https://pubmed.ncbi.nlm.nih.gov/14580936/
• [2.4] Borjini, N., et al. (2019). Thymulin treatment attenuates inflammatory pain by modulating spinal cellular and molecular signaling pathways. International Immunopharmacology. https://pubmed.ncbi.nlm.nih.gov/30851702/
• [3.3] Haase, H., & Rink, L. (2009). The immune system and the impact of zinc during aging. Immunity & Ageing. https://pmc.ncbi.nlm.nih.gov/articles/PMC2702361/
• [3.5] (2019). Thymulin – Knowledge and References. Taylor & Francis. https://taylorandfrancis.com/knowledge/Medicine_and_healthcare/Pharmaceutical_medicine/Thymulin/
• [4.1] da Silva, A. L., et al. (2014). DNA Nanoparticle-Mediated Thymulin Gene Therapy Prevents Airway Remodeling in Experimental Allergic Asthma. Journal of Controlled Release. https://pmc.ncbi.nlm.nih.gov/articles/PMC3992277/

• Stable at room temperature for up to 90 days. For long-term storage, keep at -20°C (-4°F) or colder.
• Once mixed with a solvent (e.g., bacteriostatic water), the solution must be stored at 4 °C (39°F) and utilized within 30 days. Avoid repeated freeze-thaw cycles, as this degrades the peptide structure.

RESEARCH USE ONLY

This product is intended strictly for laboratory research use only. It is not for human or veterinary use. It is not intended for diagnosis, treatment, cure, or prevention of any disease. All purchases are subject to our Terms of Service and Purity Guarantee.

No COAs available for this product.